Teva's Generic Exclusivity For Cozaar/Hyzaar Is Upheld By District Court; Apotex Appeals

Court finds that FDA correctly followed an appeals court's reasoning in awarding Teva exclusivity; Apotex says the agency failed to make a distinction between patent delisting and expiration.